LOGIN  |  REGISTER
Recursion

Veeva Systems to Present at Upcoming Investor Conference

March 04, 2024 | Last Trade: US$215.95 4.71 -2.13

PLEASANTON, Calif., March 4, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced participation in the following investor conference:

  • Morgan Stanley Technology, Media & Telecom Conference, San Francisco, CA. Brent Bowman, CFO, is presenting on Wednesday, March 6, 2024, at 9:30 a.m. Pacific Time

The presentation will be webcast. Links to the live and archived webcast will be available on Veeva's investor relations website at https://ir.veeva.com.

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor Veeva's investor relations website in addition to following its press releases, SEC filings, and public conference calls and webcasts.

Investor Relations Contact: 
Gunnar Hansen 
Veeva Systems Inc. 
267-460-5839
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media Contact: 
Maria Scurry
Veeva Systems Inc. 
781-366-7617
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Terns Pharmaceuticals

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page